PLoS ONE (Feb 2011)

Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome.

  • Steven E Schutzer,
  • Thomas E Angel,
  • Tao Liu,
  • Athena A Schepmoes,
  • Therese R Clauss,
  • Joshua N Adkins,
  • David G Camp,
  • Bart K Holland,
  • Jonas Bergquist,
  • Patricia K Coyle,
  • Richard D Smith,
  • Brian A Fallon,
  • Benjamin H Natelson

DOI
https://doi.org/10.1371/journal.pone.0017287
Journal volume & issue
Vol. 6, no. 2
p. e17287

Abstract

Read online

BackgroundNeurologic Post Treatment Lyme disease (nPTLS) and Chronic Fatigue (CFS) are syndromes of unknown etiology. They share features of fatigue and cognitive dysfunction, making it difficult to differentiate them. Unresolved is whether nPTLS is a subset of CFS.Methods and principal findingsPooled cerebrospinal fluid (CSF) samples from nPTLS patients, CFS patients, and healthy volunteers were comprehensively analyzed using high-resolution mass spectrometry (MS), coupled with immunoaffinity depletion methods to reduce protein-masking by abundant proteins. Individual patient and healthy control CSF samples were analyzed directly employing a MS-based label-free quantitative proteomics approach. We found that both groups, and individuals within the groups, could be distinguished from each other and normals based on their specific CSF proteins (pConclusionsnPTLS and CFS have distinguishing CSF protein complements. Each condition has a number of CSF proteins that can be useful in providing candidates for future validation studies and insights on the respective mechanisms of pathogenesis. Distinguishing nPTLS and CFS permits more focused study of each condition, and can lead to novel diagnostics and therapeutic interventions.